'Penny', a SMS Text-based Chatbot Intervention for Medication Adherence and Side Effect Management Among Patients With GI Cancers

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

November 5, 2024

Study Completion Date

November 8, 2024

Conditions
Gastrointestinal Cancer
Interventions
DEVICE

'Penny' via Memora Platform

"The overall objective of this study is to evaluate the feasibility and safety of a novel SMS text- based intervention of an Algorithmically Driven Augmented Intelligence chatbot, Penny. This chat bot will walk patients through how and when to take their oral chemotherapies, as well as provide real-time management of side effects Grade II or less, and escalate to the clinical team side effects of Grade III or more, as based on the Common Terminology Criteria for Adverse Events (CTCAE), for patients that have a gastrointestinal (GI) cancer."

Trial Locations (1)

19104

Abramson Cancer Center, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT05113264 - 'Penny', a SMS Text-based Chatbot Intervention for Medication Adherence and Side Effect Management Among Patients With GI Cancers | Biotech Hunter | Biotech Hunter